Jefferies Financial Group Boosts Revvity (NYSE:RVTY) Price Target to $125.00

Revvity (NYSE:RVTY) had its target price hoisted by Jefferies Financial Group from $115.00 to $125.00 in a report released on Monday, Benzinga reports. The firm currently has a hold rating on the stock.

Several other equities analysts also recently commented on RVTY. Robert W. Baird increased their price target on Revvity from $126.00 to $127.00 and gave the company an outperform rating in a report on Tuesday, April 30th. TD Cowen increased their price target on Revvity from $123.00 to $130.00 and gave the company a buy rating in a report on Tuesday, April 30th. Leerink Partnrs upgraded Revvity to a strong-buy rating in a report on Monday, July 8th. SVB Leerink began coverage on Revvity in a report on Monday, July 8th. They set an outperform rating and a $125.00 price target on the stock. Finally, Barclays lowered their price target on Revvity from $116.00 to $115.00 and set an equal weight rating on the stock in a report on Friday, June 28th. Eight research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Revvity currently has an average rating of Moderate Buy and a consensus target price of $123.81.

Revvity Trading Down 0.5 %

NYSE:RVTY opened at $125.02 on Monday. The stock’s 50 day moving average price is $109.89 and its 200 day moving average price is $106.94. Revvity has a 52 week low of $79.50 and a 52 week high of $128.15. The company has a market capitalization of $15.43 billion, a P/E ratio of 103.32, a P/E/G ratio of 3.01 and a beta of 1.05. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.92 and a current ratio of 2.27.

Revvity (NYSE:RVTY) last released its quarterly earnings data on Monday, July 29th. The company reported $1.22 EPS for the quarter, topping analysts’ consensus estimates of $1.12 by $0.10. Revvity had a return on equity of 7.34% and a net margin of 6.26%. The firm had revenue of $691.70 million for the quarter, compared to the consensus estimate of $690.33 million. During the same quarter in the prior year, the company posted $1.21 earnings per share. The firm’s revenue was down 2.5% on a year-over-year basis. On average, research analysts forecast that Revvity will post 4.76 EPS for the current fiscal year.

Revvity Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, November 8th. Investors of record on Friday, October 18th will be given a $0.07 dividend. The ex-dividend date is Friday, October 18th. This represents a $0.28 annualized dividend and a yield of 0.22%. Revvity’s dividend payout ratio (DPR) is currently 23.14%.

Insider Buying and Selling

In related news, insider Joel S. Goldberg sold 4,000 shares of the firm’s stock in a transaction on Friday, June 7th. The stock was sold at an average price of $110.46, for a total value of $441,840.00. Following the completion of the transaction, the insider now directly owns 36,900 shares of the company’s stock, valued at $4,075,974. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Rhumbline Advisers lifted its holdings in shares of Revvity by 0.4% during the second quarter. Rhumbline Advisers now owns 211,814 shares of the company’s stock valued at $22,211,000 after acquiring an additional 754 shares during the period. Natixis Advisors LLC bought a new position in shares of Revvity during the second quarter valued at $1,111,000. Triodos Investment Management BV lifted its holdings in shares of Revvity by 7.6% during the second quarter. Triodos Investment Management BV now owns 15,600 shares of the company’s stock valued at $1,636,000 after acquiring an additional 1,100 shares during the period. nVerses Capital LLC bought a new position in shares of Revvity during the second quarter valued at $73,000. Finally, Rothschild Investment LLC acquired a new stake in shares of Revvity in the second quarter valued at $25,000. 86.65% of the stock is owned by institutional investors.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.